AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27309266 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser for 30 seconds
Number of subjects: 0
Study 27309266 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 0
Study 24942954 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive dietary guidelines provided in an educational booklet for 4-6 weeks during disease flare.
Number of subjects: 112
Study 24942954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary guidelines).
Number of subjects: 112
Study 22471650 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐Health Educational Program
Number of subjects: 150
Study 22471650 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living Information
Number of subjects: 150
Study 20217051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 71
Study 20217051 — intervention group
Group type: COMPARATOR
Intervention: Denic cigarettes
Number of subjects: 71
Study 20217051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes after overnight abstinence
Number of subjects: 71
Study 20217051 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech preparation session
Number of subjects: 71
Study 17516056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard conditioning (painful electrical conditioning stimuli applied over the sural nerve 100 ms before test stimuli)
Number of subjects: 10
Study 17516056 — intervention group
Group type: EXPERIMENTAL
Intervention: Random sequences (test‐only and conditioning‐test combinations in a double‐blind, random order)
Number of subjects: 10
Study 15101858 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) with 10 ml of 1% lidocaine
Number of subjects: 20
Study 15101858 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection (IM)
Number of subjects: 20
Study 15101858 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 20
Study 11725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis methodology
Number of subjects: 13282
Study 11725478 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 13282
Study 9829444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 500 mg b.i.d. for 10 days
Number of subjects: 1414
Study 9829444 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (CA) 250 mg b.i.d. for 10 days
Number of subjects: 1414
Study 7917535 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (50 mg/day for the first month, followed by 25 mg/day for the following months)
Number of subjects: 316
Study 7917535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 7917535 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 316
Study 2744731 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon (2.5, 5.0 or 10 X 10(6) per m2, intramuscularly, three times per week, for 24 weeks)
Number of subjects: 16
Study 2744731 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 16
Study 2744731 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivation of chronic hepatitis B
Number of subjects: 16
Study 2744731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuations in serum ALT values
Number of subjects: 16
Study 2744731 — intervention group
Group type: COMPARATOR
Intervention: Conventional indices (serum albumin, bilirubin concentrations, prothrombin time)
Number of subjects: 16
Study 332345 — intervention group
Group type: EXPERIMENTAL
Intervention: BCOP (BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone)
Number of subjects: 298
Study 332345 — intervention group
Group type: EXPERIMENTAL
Intervention: COP (cyclophosphamide, Oncovin (vincristine), and prednisone)
Number of subjects: 298
Study 332345 — intervention group
Group type: COMPARATOR
Intervention: Cycle-active therapy (methotrexate, cytosine arabinoside, and 6‐thioguanine)
Number of subjects: 298
Study 332345 — intervention group
Group type: COMPARATOR
Intervention: Good histologies
Number of subjects: 298
Study 31752543 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoelectron microscopy (IEM) with gold‐labelled antibodies against kappa light chains, lambda light chains, transthyretin and amyloid A
Number of subjects: 106
Study 31752543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser microdissection followed by tandem mass spectrometry (LMD‐MS)
Number of subjects: 106
Study 31752543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry (MS)
Number of subjects: 106
Study 31752543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of IEM and LMD‐MS
Number of subjects: 106
Study 31084337 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives (21 months)
Number of subjects: 17502
Study 31084337 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plans (9 months)
Number of subjects: 17502
Study 31084337 — intervention group
Group type: EXPERIMENTAL
Intervention: National score (4 indicators)
Number of subjects: 17502
Study 31084337 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to stroke units
Number of subjects: 17502
Study 28502545 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR with preservation of antegrade internal iliac artery perfusion using iliac branched devices (EVAR-IBD)
Number of subjects: 330
Study 28502545 — intervention group
Group type: COMPARATOR
Intervention: Standard EVAR
Number of subjects: 330
Study 25409112 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Outcomes and Coordinated-Care Management (PCCM) approach
Number of subjects: 1506
Study 25409112 — intervention group
Group type: COMPARATOR
Intervention: Conventional Diagnostic and Treatment Outpatient Medical Care (CONV) approach
Number of subjects: 1506
Study 23341418 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20-minute interventions pre- and post-surgery)
Number of subjects: 60
Study 23341418 — intervention group
Group type: COMPARATOR
Intervention: Structured attention (20-minute interventions pre- and post-surgery)
Number of subjects: 60
Study 21447470 — intervention group
Group type: EXPERIMENTAL
Intervention: WB-GTH intervention
Number of subjects: 272
Study 19375959 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable training martingales (TM)
Number of subjects: 13
Study 19375959 — intervention group
Group type: EXPERIMENTAL
Intervention: Elasticised rein inserts (RI)
Number of subjects: 13
Study 19375959 — intervention group
Group type: COMPARATOR
Intervention: Plain reins (Control)
Number of subjects: 13
Study 16971801 — intervention group
Group type: EXPERIMENTAL
Intervention: Multishot DW‐PROPELLER
Number of subjects: 12
Study 16971801 — intervention group
Group type: COMPARATOR
Intervention: Single‐shot DW‐SE‐EPI
Number of subjects: 12
Study 15274665 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 96
Study 15274665 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive gastritis
Number of subjects: 96
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blinding
Number of subjects: 91
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blinding
Number of subjects: 91
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple blinding
Number of subjects: 91
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blinding (textbook definition)
Number of subjects: 91
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blinding (textbook definition)
Number of subjects: 91
Study 11308438 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple blinding (textbook definition)
Number of subjects: 91
Study 9428580 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-enriched vegetarian diet (AVD)
Number of subjects: 13
Study 9428580 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard vegetarian diet (ALVD)
Number of subjects: 13
Study 9428580 — intervention group
Group type: COMPARATOR
Intervention: Avocado-added free diet (FDWA)
Number of subjects: 13
Study 8214744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 6
Study 8214744 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 6
Study 8214744 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (30 min after application) during spontaneous ventilation
Number of subjects: 6
Study 8214744 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia
Number of subjects: 6
Study 3441105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of timolol 0.5% and pilocarpine 2%
Number of subjects: 0
Study 3441105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of timolol 0.5% and pilocarpine 4%
Number of subjects: 0
Study 31084617 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-11 guidelines
Number of subjects: 2288
Study 31084617 — intervention group
Group type: COMPARATOR
Intervention: ICD-10 guidelines
Number of subjects: 2288
Study 29378981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser at 1.2 W
Number of subjects: 36
Study 29378981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser at 2 W
Number of subjects: 36
Study 29378981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser at 3 W
Number of subjects: 36
Study 29378981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 26516311 — intervention group
Group type: EXPERIMENTAL
Intervention: Furocyst (Trigonella foenum-graecum seed extract, 2 capsules of 500 mg each/day)
Number of subjects: 50
Study 23213055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years (arm A)
Number of subjects: 0
Study 23213055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years followed by anastrozole for 3 years (arm B)
Number of subjects: 0
Study 21982456 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time automated electronic medical record alerts for patients with estimated glomerular filtration rates <45 mL/min/1.73 m(2) recommending renal referral and urine albumin quantification if not done within the prior year.
Number of subjects: 248
Study 21982456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no automated alerts).
Number of subjects: 248
Study 18300666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous temperature-controlled cryotherapy
Number of subjects: 53
Study 18300666 — intervention group
Group type: COMPARATOR
Intervention: Ice therapy
Number of subjects: 53
Study 18300666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 16525857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lorazepam
Number of subjects: 64
Study 16525857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 64
Study 16525857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 14756914 — intervention group
Group type: EXPERIMENTAL
Intervention: 4800 microg retinol (vitamin A) + 120 mg Fe + 500 microg folic acid
Number of subjects: 276
Study 14756914 — intervention group
Group type: COMPARATOR
Intervention: 120 mg Fe + 500 microg folic acid (without vitamin A)
Number of subjects: 276
Study 14756914 — intervention group
Group type: COMPARATOR
Intervention: Governmental Fe supplementation programme (control group)
Number of subjects: 276
Study 11359657 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 administered by subcutaneous injection at a maintenance dose of 1.25 microg/kg on days 1, 8, and 15 of each 28-day cycle.
Number of subjects: 46
Study 11359657 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha 2a administered at 9 million units by subcutaneous injection three times per week.
Number of subjects: 46
Study 9408720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative meta-analysis with classical monitoring boundaries
Number of subjects: 0
Study 9408720 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial
Number of subjects: 0
Study 9408720 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal information size for a meta-analysis
Number of subjects: 0
Study 8503670 — intervention group
Group type: EXPERIMENTAL
Intervention: Autohaler inhalation device
Number of subjects: 51
Study 8503670 — intervention group
Group type: COMPARATOR
Intervention: Rotahaler
Number of subjects: 51
Study 8503670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both inhalers
Number of subjects: 51
Study 3729353 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 0
Study 3729353 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 0
Study 29642628 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based intervention (SNI) promoting water consumption among children
Number of subjects: 377
Study 29642628 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention
Number of subjects: 377
Study 27030142 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 (6, 18, and 36 mg/kg)
Number of subjects: 21
Study 27030142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25573021 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with SB
Number of subjects: 90
Study 25573021 — intervention group
Group type: COMPARATOR
Intervention: APC alone
Number of subjects: 90
Study 25573021 — intervention group
Group type: COMPARATOR
Intervention: SB alone
Number of subjects: 90
Study 22562730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and continuous running training (SCR)
Number of subjects: 44
Study 22562730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and interval running training (SIR)
Number of subjects: 44
Study 22562730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent strength and continuous cycle ergometer training (SCE)
Number of subjects: 44
Study 22562730 — intervention group
Group type: COMPARATOR
Intervention: Strength training only (STO)
Number of subjects: 44
Study 19709658 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT), autologous blood exposed to oxygen/ozone gas mixture by intragluteal injection, administered on day 1, 2, 7, and once a week thereafter for at least 22 weeks.
Number of subjects: 151
Study 19709658 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered to control group (n=74).
Number of subjects: 151
Study 19709658 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT).
Number of subjects: 151
Study 19709658 — intervention group
Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 151
Study 18489229 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive training in auditory identification tasks
Number of subjects: 0
Study 18489229 — intervention group
Group type: COMPARATOR
Intervention: Extensive training with highly similar sounds
Number of subjects: 0
Study 11395345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidimensional preventive programme (n = 250)
Number of subjects: 503
Study 11395345 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 249)
Number of subjects: 503
Study 11395345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidimensional preventive programme
Number of subjects: 503
Study 9513325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose midazolam (MZ) administered i.v. at doses of 0, 0.03, 0.06 mg.kg‐1
Number of subjects: 70
Study 9513325 — intervention group
Group type: COMPARATOR
Intervention: No premedication (group N)
Number of subjects: 70
Study 8151609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg once daily)
Number of subjects: 111
Study 8151609 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard (20‐40 mg twice daily)
Number of subjects: 111
Study 8151609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 111
Study 8151609 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard
Number of subjects: 111
Study 2855391 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocote (alginic acid, aluminium hydroxide gel, magnesium trisilicate, sodium bicarbonate) 2 tablets q.d.s.
Number of subjects: 0
Study 2855391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg q.d.s.
Number of subjects: 0
Study 2855391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Cimetidine and Gastrocote)
Number of subjects: 0
Study 2855391 — intervention group
Group type: COMPARATOR
Intervention: Gastrocote
Number of subjects: 0
Study 2855391 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 2855391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 0
Study 31179505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear with light force (300 g)
Number of subjects: 40
Study 31179505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear with heavy force (500 g)
Number of subjects: 40
Study 28109570 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 80
Study 25627646 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training program (throwing movement with a medicine ball)
Number of subjects: 34
Study 25627646 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular throwing training (throwing with regular balls)
Number of subjects: 34
Study 25627646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 22895636 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based pedagogy for sustainability ethics
Number of subjects: 0
Study 22895636 — intervention group
Group type: COMPARATOR
Intervention: Traditional professional ethics education
Number of subjects: 0
Study 21871056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 76
Study 21871056 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 76
Study 17562336 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day (n = 72)
Number of subjects: 137
Study 17562336 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day (n = 65)
Number of subjects: 137
Study 17562336 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day
Number of subjects: 137
Study 17562336 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day
Number of subjects: 137
Study 16844889 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical depression (Beck Depression Inventory)
Number of subjects: 179
Study 16844889 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical anxiety (Beck Anxiety Inventory)
Number of subjects: 179
Study 12404072 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hydrocodone/1.5 mg homatropine
Number of subjects: 18
Study 12404072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocodone/3 mg homatropine
Number of subjects: 18
Study 12404072 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocodone/6 mg homatropine
Number of subjects: 18
Study 12404072 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg morphine
Number of subjects: 18
Study 12404072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18
Study 12404072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10705173 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone 1.5 g/day for 8 weeks (PHG(+)‐t)
Number of subjects: 45
Study 10705173 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone 1.5 g/day for 8 weeks (PHG(‐)‐t)
Number of subjects: 45
Study 10705173 — intervention group
Group type: COMPARATOR
Intervention: No treatment (PHG(+)‐n)
Number of subjects: 45
Study 9552427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopressor (metoprolol tartrate)
Number of subjects: 4
Study 9552427 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-dissolving formulation
Number of subjects: 4
Study 9552427 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dissolving formulation
Number of subjects: 4
Study 9552427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving formulation
Number of subjects: 4
Study 8400793 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 20
Study 8400793 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31531949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB medications
Number of subjects: 49
Study 31531949 — intervention group
Group type: COMPARATOR
Intervention: Control group (TB patients without gout attacks)
Number of subjects: 49
Study 31531949 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI, CKD, and pre-treatment hyperuricemia (SUA ≥ 6.8 mg/dL)
Number of subjects: 49
Study 30541250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 84
Study 30541250 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 84
Study 27827331 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-led video
Number of subjects: 87
Study 27827331 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-generated community video
Number of subjects: 87
Study 27827331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physician-led and subject-generated videos
Number of subjects: 87
Study 27827331 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet (control group)
Number of subjects: 87
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT thickness measured via echocardiography in patients with CAD
Number of subjects: 153
Study 25200587 — intervention group
Group type: COMPARATOR
Intervention: EAT thickness measured via echocardiography in patients without CAD
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT thickness from parasternal short-axis view in patients with CAD
Number of subjects: 153